Published in Nat Genet on October 24, 2004
Sialic acids in human health and disease. Trends Mol Med (2008) 2.61
Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev (2011) 1.93
Neurology of inherited glycosylation disorders. Lancet Neurol (2012) 1.82
Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet (2009) 1.77
Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases. J Inherit Metab Dis (2012) 1.66
Identification of host cell factors required for intoxication through use of modified cholera toxin. J Cell Biol (2011) 1.47
Metabolic glycoengineering: sialic acid and beyond. Glycobiology (2009) 1.45
Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth. Proc Natl Acad Sci U S A (2005) 1.44
Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc Natl Acad Sci U S A (2005) 1.43
On the nomenclature of congenital disorders of glycosylation (CDG). J Inherit Metab Dis (2008) 1.38
The role of glycosphingolipid metabolism in the developing brain. J Lipid Res (2008) 1.37
Myelin-associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: neuropathology and behavioral deficits in single- and double-null mice. Exp Neurol (2005) 1.32
Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Physiol Rev (2014) 1.32
Glycosylation diseases: quo vadis? Biochim Biophys Acta (2008) 1.30
Brain gangliosides in axon-myelin stability and axon regeneration. FEBS Lett (2009) 1.30
Lysosomal storage disorders in the newborn. Pediatrics (2009) 1.29
Neurological aspects of human glycosylation disorders. Annu Rev Neurosci (2015) 1.27
Lysosomal lipid storage diseases. Cold Spring Harb Perspect Biol (2011) 1.26
Multi-system disorders of glycosphingolipid and ganglioside metabolism. J Lipid Res (2010) 1.22
Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia. Am J Hum Genet (2013) 1.15
Functional roles of gangliosides in neurodevelopment: an overview of recent advances. Neurochem Res (2012) 1.14
Structures, biosynthesis, and functions of gangliosides--an overview. J Oleo Sci (2011) 1.11
Reduced ceramide synthase 2 activity causes progressive myoclonic epilepsy. Ann Clin Transl Neurol (2014) 1.11
Sphingolipid lysosomal storage disorders. Nature (2014) 1.08
Defective mitochondrial mRNA maturation is associated with spastic ataxia. Am J Hum Genet (2010) 1.08
Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases. Expert Rev Mol Med (2010) 1.04
Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction. J Physiol (2009) 1.01
Golgi glycosylation and human inherited diseases. Cold Spring Harb Perspect Biol (2011) 0.99
Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis. Brain (2013) 0.93
Ablation of neuronal ceramide synthase 1 in mice decreases ganglioside levels and expression of myelin-associated glycoprotein in oligodendrocytes. J Biol Chem (2012) 0.93
A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation. Hum Mol Genet (2013) 0.93
Membrane glycolipids in stem cells. FEBS Lett (2009) 0.93
Ganglioside synthase knockout in oncogene-transformed fibroblasts depletes gangliosides and impairs tumor growth. Oncogene (2010) 0.92
Differential regulation of sphingomyelin synthesis and catabolism in oligodendrocytes and neurons. J Neurochem (2008) 0.91
Approaches to homozygosity mapping and exome sequencing for the identification of novel types of CDG. Glycoconj J (2012) 0.90
Ganglioside biochemistry. ISRN Biochem (2012) 0.89
Refractory epilepsy and mitochondrial dysfunction due to GM3 synthase deficiency. Eur J Hum Genet (2012) 0.89
The Angelman syndrome protein Ube3a/E6AP is required for Golgi acidification and surface protein sialylation. J Neurosci (2013) 0.89
Exogenous gangliosides increase the release of brain-derived neurotrophic factor. Neuropharmacology (2010) 0.84
Gangliosides help stabilize the brain. Nat Genet (2004) 0.84
NANS-mediated synthesis of sialic acid is required for brain and skeletal development. Nat Genet (2016) 0.84
Roles of gangliosides in mouse embryogenesis and embryonic stem cell differentiation. Exp Mol Med (2011) 0.84
Targeted sequencing of 351 candidate genes for epileptic encephalopathy in a large cohort of patients. Mol Genet Genomic Med (2016) 0.83
The role of gangliosides in neurodevelopment. Nutrients (2015) 0.83
Ganglioside regulation of AMPA receptor trafficking. J Neurosci (2014) 0.83
Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation. Genet Med (2016) 0.83
Neuronal expression of GalNAc transferase is sufficient to prevent the age-related neurodegenerative phenotype of complex ganglioside-deficient mice. J Neurosci (2014) 0.82
Physiologic and pathophysiologic consequences of altered sialylation and glycosylation on ion channel function. Biochem Biophys Res Commun (2014) 0.82
The clinical spectrum of inherited diseases involved in the synthesis and remodeling of complex lipids. A tentative overview. J Inherit Metab Dis (2014) 0.82
Tumor gangliosides accelerate murine tumor angiogenesis. Angiogenesis (2013) 0.82
Insights into complexity of congenital disorders of glycosylation. Biochem Med (Zagreb) (2012) 0.81
HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease. Front Pharmacol (2014) 0.81
Differential distribution of major brain gangliosides in the adult mouse central nervous system. PLoS One (2013) 0.81
miRNA proxy approach reveals hidden functions of glycosylation. Proc Natl Acad Sci U S A (2015) 0.81
Human genetic disorders of sphingolipid biosynthesis. J Inherit Metab Dis (2014) 0.81
Skin manifestations in CDG. J Inherit Metab Dis (2014) 0.80
Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice. J Inherit Metab Dis (2010) 0.80
Gangliosides of the Vertebrate Nervous System. J Mol Biol (2016) 0.80
Simplifying complexity: genetically resculpting glycosphingolipid synthesis pathways in mice to reveal function. Glycoconj J (2014) 0.80
How Do Gangliosides Regulate RTKs Signaling? Cells (2013) 0.79
Production of multiple brain-like ganglioside species is dispensable for fas-induced apoptosis of lymphoid cells. PLoS One (2011) 0.79
Sialylation regulates brain structure and function. FASEB J (2015) 0.78
Human genetic disorders involving glycosylphosphatidylinositol (GPI) anchors and glycosphingolipids (GSL). J Inherit Metab Dis (2014) 0.78
Implications for the mammalian sialidases in the physiopathology of skeletal muscle. Skelet Muscle (2012) 0.78
Activities of genes controlling sphingolipid metabolism in human fibroblasts treated with flavonoids. Metab Brain Dis (2015) 0.77
Adaptive control model reveals systematic feedback and key molecules in metabolic pathway regulation. J Comput Biol (2011) 0.77
The consequences of genetic and pharmacologic reduction in sphingolipid synthesis. J Inherit Metab Dis (2014) 0.76
Ganglioside GM3 is essential for the structural integrity and function of cochlear hair cells. Hum Mol Genet (2015) 0.76
Apprehending ganglioside diversity: a comprehensive methodological approach. J Lipid Res (2015) 0.76
Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents. Front Oncol (2016) 0.76
The α2B-adrenergic receptor is mutant in cortical myoclonus and epilepsy. Ann Neurol (2014) 0.76
Role of Cytokine-Induced Glycosylation Changes in Regulating Cell Interactions and Cell Signaling in Inflammatory Diseases and Cancer. Cells (2016) 0.75
A new assay for determining ganglioside sialyltransferase activities lactosylceramide-2,3-sialyltransferase (SAT I) and monosialylganglioside-2,3-sialyltransferase (SAT IV). PLoS One (2014) 0.75
Ganglioside Profiling of the Human Retina: Comparison with Other Ocular Structures, Brain and Plasma Reveals Tissue Specificities. PLoS One (2016) 0.75
Ganglioside deficiency causes inflammation and neurodegeneration via the activation of complement system in the spinal cord. J Neuroinflammation (2014) 0.75
Lipid glycosylation: a primer for histochemists and cell biologists. Histochem Cell Biol (2016) 0.75
Identification and Functional Characterization of ST3GAL5 and ST8SIA1 Variants in Patients with Thyroid-Associated Ophthalmopathy. Yonsei Med J (2017) 0.75
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol (2007) 4.96
Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci (2008) 4.63
Convergence of electronic bands for high performance bulk thermoelectrics. Nature (2011) 4.52
Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med (2008) 3.86
Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol (2002) 3.53
Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol (2008) 3.49
Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry (2008) 3.47
Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. Glycobiology (2003) 3.19
Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature (2007) 3.13
Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature (2007) 3.01
Individual differences in reward responding explain placebo-induced expectations and effects. Neuron (2007) 2.96
Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics (2009) 2.93
PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet (2002) 2.81
Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology (2007) 2.71
Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A (2005) 2.70
The identification of a conserved domain in both spartin and spastin, mutated in hereditary spastic paraplegia. Genomics (2003) 2.69
The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A (2003) 2.64
Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol (2008) 2.63
Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med (2007) 2.57
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A (2010) 2.51
Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet (2004) 2.50
Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I. Science (2011) 2.47
Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest (2008) 2.46
Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology (2007) 2.45
Glycoprotein structural genomics: solving the glycosylation problem. Structure (2007) 2.40
SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia. Nat Genet (2002) 2.27
Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci U S A (2007) 2.24
Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet (2009) 2.22
Contrasting IgG structures reveal extreme asymmetry and flexibility. J Mol Biol (2002) 2.10
The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog (2008) 2.09
Conformational studies of oligosaccharides and glycopeptides: complementarity of NMR, X-ray crystallography, and molecular modelling. Chem Rev (2002) 2.02
PAMAM nanoparticles promote acute lung injury by inducing autophagic cell death through the Akt-TSC2-mTOR signaling pathway. J Mol Cell Biol (2009) 2.00
Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine (2010) 1.99
3D analysis of facial morphology. Am J Med Genet A (2004) 1.95
Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov (2002) 1.95
The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One (2011) 1.95
Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc Natl Acad Sci U S A (2007) 1.92
HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem (2007) 1.92
Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology (2003) 1.91
Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception. Proc Natl Acad Sci U S A (2002) 1.88
Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem (2010) 1.85
Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci U S A (2007) 1.84
Purified TPC isoforms form NAADP receptors with distinct roles for Ca(2+) signaling and endolysosomal trafficking. Curr Biol (2010) 1.84
Emerging principles for the therapeutic exploitation of glycosylation. Science (2014) 1.83
Antiviral effects of an iminosugar derivative on flavivirus infections. J Virol (2002) 1.80
A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma. J Lipid Res (2011) 1.76
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75
Arterial ischemic stroke risk factors: the International Pediatric Stroke Study. Ann Neurol (2011) 1.75
A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet (2009) 1.71
Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem (2003) 1.68
Molecular mechanisms of endolysosomal Ca2+ signalling in health and disease. Biochem J (2011) 1.68
Early menopausal hormone use influences brain regions used for visual working memory. Menopause (2010) 1.67
Storage solutions: treating lysosomal disorders of the brain. Nat Rev Neurosci (2005) 1.65
Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration. Am J Hum Genet (2008) 1.65
GlycoBase and autoGU: tools for HPLC-based glycan analysis. Bioinformatics (2008) 1.64
Homozygous mutation in SAMHD1 gene causes cerebral vasculopathy and early onset stroke. Proc Natl Acad Sci U S A (2011) 1.62
Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology (2005) 1.60
Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J Exp Med (2006) 1.57
A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology (2008) 1.55
Is the transportation highway the right road for hereditary spastic paraplegia? Am J Hum Genet (2002) 1.53
Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem (2007) 1.52
Genes contributing to prion pathogenesis. J Gen Virol (2008) 1.51
Dominant mutations in the cation channel gene transient receptor potential vanilloid 4 cause an unusual spectrum of neuropathies. Brain (2010) 1.51
Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis (2004) 1.50
Structural and quantitative analysis of N-linked glycans by matrix-assisted laser desorption ionization and negative ion nanospray mass spectrometry. Anal Biochem (2008) 1.49
Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic (2010) 1.49
Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology (2007) 1.49
Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J Biol Chem (2005) 1.47
Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum Mutat (2010) 1.44
The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc Natl Acad Sci U S A (2009) 1.44
Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine (2007) 1.44